Tuberculosis (TB) is one of the oldest infections afflicting humans yet remains the number
one infectious disease killer worldwide. Despite decades of experience treating this disease,
TB regimens require months of multidrug therapy, even for latent infections. There have
been important recent advances in treatment options across the spectrum of TB, from latent
infection to extensively drug-resistant (XDR) TB disease. In addition, new, potent drugs are
emerging out of the development pipeline and are being tested in novel regimens in multiple …